arrow
R

Richard J. Lin

Memorial Sloan Kettering Cancer Center
H指数:48
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Pilot Study of Condensed Busulfan, Melphalan, and Fludarabine Myeloablative Conditioning in Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation

一项关于浓缩白消安、美法仑和氟达拉滨骨髓清除性预处理在体外CD34⁺选择的同种异基因造血细胞移植中的初步研究

2026-10-150
PRE
Characterization of TPO Receptor Agonists for the Management of Thrombocytopenia after CAR T-cell Therapy

TPO受体激动剂用于治疗CAR T细胞治疗后血小板减少症的特征

2026-02-030
PRE
Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study

基于模型的抗胸腺细胞球蛋白剂量在体外CD34+选择的同种异基因造血细胞移植中的应用:一项单中心、单臂、II期研究

2025-12-010
PRE
Outcomes of terminal complement blockade in adults with high-risk transplant-associated thrombotic microangiopathy: a comparative analysis

高危移植相关血栓性微血管病成人中终末补体阻滞的结局:一项比较分析

2025-11-280
PRE
Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact

大B细胞淋巴瘤中CAR T细胞疗法后的晚期血液学毒性:发生率、危险因素及临床影响

2025-11-180
PRE
Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphoma

CD19 CAR-T疗法后大B细胞淋巴瘤患者糖皮质激素使用模式与安全性

2025-11-010
OAAI
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma

CD19靶向CAR T细胞疗法在大型B细胞淋巴瘤中的比较真实世界结果

2025-08-190
OAAI
Aging-related, senescence-associated secretory phenotype and allogeneic hematopoietic cell transplantation outcomes in older patients

与年龄相关、衰老相关分泌表型及同种异基因造血细胞移植在老年患者中的结局

2025-08-190
PRE
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies

嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤后的体液疫苗反应

2025-07-020
OAAI
Assessing Cognitive Function in Transplantation and CAR-T Recipients: Expert Recommendations from the Survivorship, Aging and Biobehavioral Special Interest Groups of ASTCT

评估移植和CAR-T接受者的认知功能:ASTCT生存率、老龄化和生物行为特别兴趣小组的专家建议

2025-07-010
PRE
Bone marrow and blood demonstrate distinct immune reconstitution patterns and correlations with relapse posttransplant

骨髓和血液显示出不同的免疫重建模式,并与移植后的复发存在关联。

2025-06-140
OAAI
Assessing Physical Function in Transplantation and CAR-T Recipients: Expert Recommendations from the Survivorship, Aging and Biobehavioral Special Interest Groups of ASTCT

评估移植和CAR-T接受者的躯体功能:ASTCT生存、衰老与生物行为特别兴趣小组的专家建议

2025-06-010
PRE
US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines

美国老年评估实践:针对接受造血细胞移植或嵌合抗原受体T细胞治疗的老年人——移植与细胞治疗学会老年特别兴趣小组与实践指南委员会医师调查

2025-02-010
PRE
Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort

在接受CD19 CAR T细胞治疗的淋巴瘤患者中,从广泛的抗真菌预防转变为量身定制的抗真菌预防: 来自大型回顾性队列的结果

2025-01-010
OAAI
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy

CD19嵌合抗原受体T细胞治疗后肾损伤的预测及意义

2024-11-211
OAAI
CENTRAL NERVOUS SYSTEM BRIDGING RADIOTHERAPY (CNS-BRT) ACHIEVES RAPID CYTOREDUCTION PRIOR TO CAR T-CELL THERAPY FOR AGGRESSIVE B-CELL LYMPHOMAS

中枢神经系统桥接放疗 (cns-brt) 在CAR T细胞治疗侵袭性b细胞淋巴瘤之前实现了快速的细胞减少

2024-11-110
PRE
Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study

广谱抗生素暴露对B细胞淋巴瘤CAR-T治疗效果的影响:一项多中心国际研究

BLOOD
IF23.1
2024-11-050
PRE
CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas

CNS桥接放疗在CAR T细胞治疗侵袭性b细胞淋巴瘤之前实现了快速的细胞减少

2024-10-084
OAAI
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma

淋巴瘤患者CD19-Targeted嵌合抗原受体T细胞后的后续恶性肿瘤

2024-10-013
PRE